Regeneron Pharmaceuticals Inc (NASDAQ:REGN) CFO Robert E. Landry sold 400 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $612.57, for a total transaction of $245,028.00. Following the sale, the chief financial officer now directly owns 24,334 shares in the company, valued at $14,906,278.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NASDAQ:REGN opened at $623.65 on Wednesday. The company has a 50-day moving average of $593.41 and a 200-day moving average of $476.16. The firm has a market cap of $67.71 billion, a price-to-earnings ratio of 31.34, a price-to-earnings-growth ratio of 1.93 and a beta of 0.57. The company has a current ratio of 4.21, a quick ratio of 3.49 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals Inc has a twelve month low of $271.37 and a twelve month high of $646.33.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The firm had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the previous year, the business posted $4.45 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals Inc will post 23.48 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Parkside Financial Bank & Trust raised its position in shares of Regeneron Pharmaceuticals by 44.2% in the first quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 19 shares during the period. Icon Wealth Partners LLC boosted its holdings in Regeneron Pharmaceuticals by 3.8% during the first quarter. Icon Wealth Partners LLC now owns 659 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 24 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,149 shares of the biopharmaceutical company’s stock valued at $1,048,000 after buying an additional 29 shares during the period. Investment House LLC increased its holdings in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Investment House LLC now owns 1,210 shares of the biopharmaceutical company’s stock worth $591,000 after acquiring an additional 30 shares in the last quarter. Finally, CX Institutional increased its stake in Regeneron Pharmaceuticals by 144.0% during the 1st quarter. CX Institutional now owns 61 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.
A number of brokerages recently weighed in on REGN. ValuEngine raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Benchmark initiated coverage on Regeneron Pharmaceuticals in a report on Sunday, April 19th. They set a “hold” rating for the company. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $400.00 to $624.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 2nd. Finally, Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $409.00 to $555.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Fifteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $548.86.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: What is the FTSE 100 index?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.